vs
Side-by-side financial comparison of Strive, Inc. (ASST) and Dianthus Therapeutics, Inc. (DNTH). Click either name above to swap in a different company.
Dianthus Therapeutics, Inc. is the larger business by last-quarter revenue ($284.0K vs $255.0K, roughly 1.1× Strive, Inc.). Dianthus Therapeutics, Inc. runs the higher net margin — -22687.3% vs -75406.7%, a 52719.3% gap on every dollar of revenue. On growth, Strive, Inc. posted the faster year-over-year revenue change (-74.1% vs -78.6%). Over the past eight quarters, Strive, Inc.'s revenue compounded faster (77.6% CAGR vs -44.6%).
Strive Asset Management is an American investment management firm founded in 2022. The firm operates mutual funds, exchange-traded products (ETPs), and wealth management services. Headquartered in Columbus, Ohio, it operates as a subsidiary of Strive Enterprises, Inc. and is registered with the U.S. Securities and Exchange Commission (SEC) as an investment adviser.
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
ASST vs DNTH — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $255.0K | $284.0K |
| Net Profit | $-192.3M | $-64.4M |
| Gross Margin | — | — |
| Operating Margin | -17288.6% | -24486.3% |
| Net Margin | -75406.7% | -22687.3% |
| Revenue YoY | -74.1% | -78.6% |
| Net Profit YoY | -2726.9% | -126.6% |
| EPS (diluted) | $-0.22 | $-1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $284.0K | ||
| Q3 25 | $255.0K | $396.0K | ||
| Q2 25 | $173.3K | — | ||
| Q1 25 | $170.7K | $1.2M | ||
| Q4 24 | $212.8K | $1.3M | ||
| Q3 24 | $984.0K | $2.2M | ||
| Q2 24 | $93.0K | $1.9M | ||
| Q1 24 | $124.8K | $874.0K |
| Q4 25 | — | $-64.4M | ||
| Q3 25 | $-192.3M | $-36.8M | ||
| Q2 25 | $-8.9M | — | ||
| Q1 25 | $-3.7M | $-29.5M | ||
| Q4 24 | $-4.1M | $-28.4M | ||
| Q3 24 | $-6.8M | $-25.2M | ||
| Q2 24 | $-5.9M | $-17.6M | ||
| Q1 24 | $-4.8M | $-13.7M |
| Q4 25 | — | -24486.3% | ||
| Q3 25 | -17288.6% | -10173.7% | ||
| Q2 25 | -1553.9% | — | ||
| Q1 25 | -970.5% | -2852.7% | ||
| Q4 24 | -5889.5% | -2406.9% | ||
| Q3 24 | -712.4% | -1376.6% | ||
| Q2 24 | -1857.2% | -1191.8% | ||
| Q1 24 | -1110.9% | -2041.6% |
| Q4 25 | — | -22687.3% | ||
| Q3 25 | -75406.7% | -9284.1% | ||
| Q2 25 | -5122.4% | — | ||
| Q1 25 | -2195.6% | -2537.5% | ||
| Q4 24 | -1935.5% | -2144.8% | ||
| Q3 24 | -691.3% | -1159.0% | ||
| Q2 24 | -6313.1% | -945.1% | ||
| Q1 24 | -3837.7% | -1573.0% |
| Q4 25 | — | $-1.53 | ||
| Q3 25 | $-0.22 | $-0.97 | ||
| Q2 25 | $-0.17 | — | ||
| Q1 25 | $-0.13 | $-0.82 | ||
| Q4 24 | $-5.62 | $-0.76 | ||
| Q3 24 | $-3.06 | $-0.74 | ||
| Q2 24 | $-0.58 | $-0.51 | ||
| Q1 24 | $-0.49 | $-0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $109.1M | $404.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $779.4M | $493.4M |
| Total Assets | $792.6M | $530.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $404.3M | ||
| Q3 25 | $109.1M | $402.6M | ||
| Q2 25 | $2.5M | — | ||
| Q1 25 | $4.2M | $263.2M | ||
| Q4 24 | $6.2M | $275.2M | ||
| Q3 24 | $2.1M | $281.1M | ||
| Q2 24 | $1.9M | $360.7M | ||
| Q1 24 | $1.9M | $377.0M |
| Q4 25 | — | $493.4M | ||
| Q3 25 | $779.4M | $546.5M | ||
| Q2 25 | $10.7M | — | ||
| Q1 25 | $19.6M | $328.6M | ||
| Q4 24 | $23.3M | $352.5M | ||
| Q3 24 | $27.5M | $337.9M | ||
| Q2 24 | $5.4M | $358.2M | ||
| Q1 24 | $11.3M | $372.7M |
| Q4 25 | — | $530.9M | ||
| Q3 25 | $792.6M | $577.4M | ||
| Q2 25 | $3.3M | — | ||
| Q1 25 | $5.0M | $348.6M | ||
| Q4 24 | $28.2M | $374.0M | ||
| Q3 24 | $2.6M | $354.2M | ||
| Q2 24 | $2.4M | $369.0M | ||
| Q1 24 | $2.1M | $382.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.0M | $-47.0M |
| Free Cash FlowOCF − Capex | — | $-47.1M |
| FCF MarginFCF / Revenue | — | -16591.9% |
| Capex IntensityCapex / Revenue | 0.0% | 48.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-132.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-47.0M | ||
| Q3 25 | $-14.0M | $-30.6M | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-1.6M | $-27.6M | ||
| Q4 24 | $-21.6M | $-27.4M | ||
| Q3 24 | $-13.2M | $-21.3M | ||
| Q2 24 | $-1.3M | $-14.5M | ||
| Q1 24 | $-1.0M | $-14.9M |
| Q4 25 | — | $-47.1M | ||
| Q3 25 | — | $-30.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-27.7M | ||
| Q4 24 | $-21.6M | $-27.5M | ||
| Q3 24 | $-13.4M | $-21.3M | ||
| Q2 24 | $-1.3M | $-14.5M | ||
| Q1 24 | $-1.1M | $-15.0M |
| Q4 25 | — | -16591.9% | ||
| Q3 25 | — | -7717.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -2377.8% | ||
| Q4 24 | -10161.2% | -2072.0% | ||
| Q3 24 | -1360.3% | -980.3% | ||
| Q2 24 | -1379.4% | -780.7% | ||
| Q1 24 | -844.7% | -1713.2% |
| Q4 25 | — | 48.6% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | 11.3% | 2.3% | ||
| Q3 24 | 18.8% | 1.2% | ||
| Q2 24 | 3.1% | 0.9% | ||
| Q1 24 | 9.5% | 3.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
